Amplia Therapeutics Ltd has released a press release.
Dr John Lambert appointed as new CEO
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Capital Raising for Clinical-Enabling Studies
- Preliminary Final Report - Year Ended 31 March 2019
- Appendix 4C - Quarterly Statement of Cash Flows
- European Patent Completes IP Protection in Major Markets
- Appendix 4C - December 2018 Quarter Cashflow Statement
Later from Amplia Therapeutics
- Rights Issue Prospectus
- Amplia Therapeutics Reports Lead Candidate Preclinical Data
- RightsIssue Participation Supports Clinical-Enabling Studies
- Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr
- App 4C - Sep 2019 Qtr Cash Flows Statement
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics